Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fenji
- Development stage
- Unknown
- Lead developer
- Citi Pharma
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Fenji (also marketed as Fenji Drops) is an oral herbal and nutraceutical formulation developed and manufactured by Citi Pharma in Pakistan. It is composed of a mixture of botanical extracts, including *Foeniculum vulgare* (fennel), *Mentha piperita* (peppermint), *Cuminum cyminum* (cumin), *Zingiber officinale* (ginger), and *Ptychotis ajowan* (ajwain). Fenji is indicated for the relief of digestive discomfort, bloating, and abdominal cramps, particularly in pediatric or general gastrointestinal care.
- Brand names
- FenjiFenji Drops
- Other names
- Fenji Drops
Beyond the preview
Go deeper on Fenji.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fenji.